$24.02
+0.70 (+3.00%)
Open$24.14
Previous Close$23.32
Day High$24.19
Day Low$23.70
52W High$28.49
52W Low$9.03
Volume—
Avg Volume682.2K
Market Cap1.85B
P/E Ratio—
EPS$-1.08
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-25.6% upside
Current
$24.02
$24.02
Target
$17.86
$17.86
$12.55
$17.86 avg
$20.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 106.17M | 167.01M | 182.20M |
| Net Income | -81,283,875 | -115,078,633 | 28.41M |
| Profit Margin | -76.6% | -72.7% | 15.6% |
| EBITDA | -88,997,495 | -132,999,245 | 52.86M |
| Free Cash Flow | — | — | 21.80M |
| Rev Growth | -36.4% | -36.4% | +8.1% |
| Debt/Equity | — | — | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |